|
【参考文献】
1 Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000;41(9):25142522
2 Cursiefen C, Rummelt C, Kuchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor α, and transforming growth factor β1 in human corneas with neovascularization. Cornea 2000;19(4):526533
3 Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound and inflammation related corneal neovascularization. Invest Ophthalmol Vis Sci 1998;39(1):1822
4 周炼红，邢怡桥，张云成.角膜碱烧伤后VEGF的表达与新生血管的关系.眼科新进展 2005;25(4)：315317
5 杨艳，张明昌，张波.血管内皮生长因子及其受体在大鼠碱烧伤后角膜新生血管中的表达.国际眼科杂志 2006;6(6)：13201322
6 Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin),a humanized antiVEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333(2):328335
7 Michels S, Rosenfeld PJ, Puliafito CA. Systemic bevacizumab(Avastin) therapy for neovascular agerelated macular degeneration twelveweek results of an uncontrolled openlabel clinical study. Ophthalmology 2005;112(6):10351047
8 Ahmed A, Berati H, Nalan A, et al. Effect of bevacizumab on corneal neovascularization in experimental rabbit model. Clin Experiment Ophthalmol 2009;37(7):730736
9 Papathanassiou M, Theodossiadis PG, Liarakos VS, et al. Inhibition of Corneal Neovascularization by Subconjunctival Bevacizumab in an Animal Model. Am J Ophthalmol 2008;145(3):424431
10 Hurmeric V, Mumcuoglu T, Erdurman C, et al. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea 2008;27 (3):357362
11 HabotWilner Z, Barequet IS, Ivanir Y, et al. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization. Acta Ophthalmol 2009 Jun 22.Epub ahead of print
12 Hashemian MN, Moghimi S, Kiumehr S, et al. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats. Ophthalmic Res 2009;42(2):9095
13 Chen WL, Lin CT, Lin NT, et al. Subconjunctival injection of bevacizumab (Avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci 2009;50(4):16591665
14 Saravia M,Zapata G,Ferraiolo P, et al. AntiVEGF monoclonal antibodyinduced regression of corneal neovascularization and inflammation in a rabbit model of herpetic stromal keratitis. Graefes Arch Clin Exp Ophthalmol 2009;247(10):14091416
15 Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br J Ophthalmol 2007;91(6):804807
16 Barros LF, Belfort JR. The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. An Acad Bras Cienc 2007;79(3):389394
17 Barros LF, Belfort R Jr. The effects of the subconjunctival injection of bevacizumab(Avastin)on angiogenesis in the rat cornea. An Acad Bras Ciênc 2007;79(3):389394
18 Jing GL, Gao XW, Ren B, et al. The inhibitory action of Bevacizumab on rat corneal neovascularization. Int J Ophthalmol(Guoji Yanke Zazhi) 2008;8(10):19551958
19 Hosseini H, Nejabat M, Mehryar M, et al. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Experiment Ophthalmol 2007;35(8):745748
20 李世宏，叶剑，贺翔鸽，等.Avastin 结膜下注射及眼液治疗角膜新生血管l 例.国际眼科杂志 2009;9(5):1010
21 Zaki AA, Farid SF. Subconjunctival bevacizumab for corneal Neovascularization. Acta Ophthalmol 2009 Jun 10.Epub ahead of print
22 Oh JY,Kim MK,Wee WR.Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy. Cornea 2009;28(9):10701073
23 Spraul CW, Grossniklaus HE, Lang GK. Primary Lipid Keratopathy. Klin Monbl Augenheilkd 2002;219(12):889891
24 Vassileva PI, Hergeldzhieva TG. Avastin use in high risk corneal transplantation. Graefes Arch Clin Exp Ophthalmol 2009;247(12):17011706
25 Saxena S, Kishore P, Pandey S, et al. Topical bevacizumab for corneal neovascularization after penetrating keratoplasty. Eur J Ophthalmol 2009;19(5):870872
26 Yoeruek E, Spitzer MS, Tatar O, et al. Safety profile of bevacizumab on cultured human corneal cells. Cornea 2007;26(8):977982
27 Kim TI, Chung JL, Hong JP, et al. Bevacizumab application delays epithelial healing in rabbit cornea. Invest Ophthalmol Vis Sci 2009;50(10):46534659
28 Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular agerelated macular degeneration. Can J Ophthalmol 2005;40(3):352368
29 Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008;115(6):3338 上一页 [1] [2] |
